Gene info: ID 9

Gene: NAT1

GENE ID: 9

Synonyms: AAC1|MNAT|NAT-1|NATI

Description: N-acetyltransferase 1

Gene type: protein-coding

Location: 8p22

dbXrefs: Ensembl:ENSG00000171428 MIM:108345 Vega:OTTHUMG00000097001 UniprotKB:P18440

RefSeq: NG_012245.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND|AD

# Publications: 90

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 6.209e-1 (AD) 4.562e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
GPR65	0.787
NABP1	0.781
DSE	0.768
TLR1	0.749
MS4A4A	0.748
TNFAIP8	0.747
DAPP1	0.746
IKBIP	0.744
ARL11	0.74
KYNU	0.739

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
KCNIP3	-0.425
BCL11A	-0.417
TMEM179	-0.416
C19orf73	-0.411
CPLX3	-0.41
ASPDH	-0.402
KCNK4	-0.393
EXTL1	-0.392
CDK5R2	-0.391
SCRT1	-0.386

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB01015	Sulfamethoxazole	Small Molecule	723-46-6	Approved	Enzyme

ID	Drug Name	Action	PubMed
C049325	1,2-dithiol-3-thione	"1,2-dithiol-3-thione results in decreased expression of NAT1 mRNA"	19162173
C015262	1,6-hexamethylene diisocyanate	"NAT1 protein polymorphism results in increased susceptibility to 1,6-hexamethylene diisocyanate"	11927838
C511295	2,2',4,4'-tetrabromodiphenyl ether	"2,2',4,4'-tetrabromodiphenyl ether analog results in decreased expression of NAT1 mRNA"	19095052
C001042	2',3-dimethyl-4-aminobiphenyl	"NAT1 protein results in increased acetylation of 2',3-dimethyl-4-aminobiphenyl"	12618593
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of NAT1 mRNA"	21346803
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	"NAT1 protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine"	18499698
C012177	2-aminofluorene	NAT1 protein results in increased acetylation of 2-aminofluorene	15627487\|1579620
C012177	2-aminofluorene	NAT1 protein results in increased acetylation of 2-aminofluorene	12618593
C012177	2-aminofluorene	NAT1 protein results in increased metabolism of 2-aminofluorene	16815960
C012177	2-aminofluorene	NAT1 protein results in increased acetylation of 2-aminofluorene	15796213
C003898	2-anisidine	NAT1 protein results in increased activity of 2-anisidine	15450435
C075748	2-(bromoacetylamino)fluorene	2-(bromoacetylamino)fluorene results in decreased activity of NAT1 protein	14714730
C075748	2-(bromoacetylamino)fluorene	2-(bromoacetylamino)fluorene results in decreased activity of and results in increased alkylation of NAT1 protein	15106881
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	"NAT1 protein affects the acetylation of and affects the activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine"	11505221
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	"NAT1 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine"	12618593
C009501	2-tolidine	NAT1 protein results in increased activity of 2-tolidine	15450435
C117220	3-nitrobenzanthrone	NAT1 protein results in increased activity of 3-nitrobenzanthrone	15805261
C117220	3-nitrobenzanthrone	[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone	20545351
C009505	4,4'-diaminodiphenylmethane	"NAT1 protein results in increased acetylation of 4,4'-diaminodiphenylmethane"	16192314
C005969	4,4'-diphenylmethane diisocyanate	"NAT1 protein polymorphism results in increased susceptibility to 4,4'-diphenylmethane diisocyanate"	11927838
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
C538896	4-amino-2-hydroxytoluene	NAT1 protein results in increased acetylation of 4-amino-2-hydroxytoluene	19100279
C013813	4-anisidine	NAT1 protein results in increased acetylation of 4-anisidine	15627487
C006757	4-biphenylamine	NAT1 mRNA alternative form affects the susceptibility to 4-biphenylamine	21837760
C006757	4-biphenylamine	NAT1 polymorphism results in increased susceptibility to 4-biphenylamine	22114069
C006757	4-biphenylamine	[NAT1 polymorphism results in increased susceptibility to 4-biphenylamine] which results in increased mutagenesis of HPRT1 gene	22114069
C006757	4-biphenylamine	NAT1 protein polymorphism results in increased acetylation of 4-biphenylamine	22010219
C006757	4-biphenylamine	NAT1 protein polymorphism results in increased susceptibility to 4-biphenylamine	22010219
C006757	4-biphenylamine	NAT1 protein results in increased acetylation of 4-biphenylamine	12088197\|2201021
C006757	4-biphenylamine	NAT1 protein results in increased activity of 4-biphenylamine	15450435
C006757	4-biphenylamine	NAT1 protein results in increased metabolism of 4-biphenylamine	16815960
C006757	4-biphenylamine	NAT1 protein results in increased metabolism of 4-biphenylamine	21837760
C023621	4-bromoaniline	NAT1 protein results in increased acetylation of 4-bromoaniline	15627487
C004658	4-chloroaniline	NAT1 protein results in increased acetylation of 4-chloroaniline	15627487
C013067	4-iodoaniline	NAT1 protein results in increased acetylation of 4-iodoaniline	15627487
C029728	4-phenylenediamine	4-phenylenediamine results in decreased activity of and results in decreased expression of NAT1 protein	20406859
C029728	4-phenylenediamine	NAT1 protein results in increased acetylation of 4-phenylenediamine	15350687
C017429	5-iodosalicylic acid	5-iodosalicylic acid results in decreased activity of NAT1 protein	15450435
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
C421010	9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole	"NAT1 protein affects the metabolism of 9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole"	17067997
D000082	Acetaminophen	Acetaminophen affects the expression of NAT1 mRNA	17562736
D000082	Acetaminophen	Acetaminophen results in increased expression of NAT1 protein	16538041
D000105	Acetyl Coenzyme A	Acetyl Coenzyme A binds to NAT1 protein	22835378
D000105	Acetyl Coenzyme A	Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]	22835378
D000105	Acetyl Coenzyme A	Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein]	22835378
D000105	Acetyl Coenzyme A	[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone	20545351
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of NAT1 gene	27153756
D016604	Aflatoxin B1	[CYP3A7 co-treated with NAT1] results in increased susceptibility to Aflatoxin B1	7625840
C518327	aloe emodin	aloe emodin results in decreased expression of and results in decreased activity of NAT1 protein	16314733
C518327	aloe emodin	aloe emodin results in decreased expression of NAT1 mRNA	16314733
D000535	Aluminum	[APP protein modified form binds to Aluminum] which results in decreased expression of NAT1 mRNA	21298039
D000588	Amines	NAT1 protein results in increased acetylation of Amines	15122594
D010129	4-Aminobenzoic Acid	NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid	14508638
D010129	4-Aminobenzoic Acid	Dehydroepiandrosterone Sulfate inhibits the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]	11470991
D010129	4-Aminobenzoic Acid	Dehydroepiandrosterone Sulfate promotes the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]	11470991
D010129	4-Aminobenzoic Acid	NAT1 protein affects the acetylation of 4-Aminobenzoic Acid	29043425
D010129	4-Aminobenzoic Acid	NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid	11470991\|1562748
D010129	4-Aminobenzoic Acid	Pentachlorophenol inhibits the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]	11470991
D010129	4-Aminobenzoic Acid	NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid	12618593
D015081	2-Naphthylamine	NAT1 protein results in increased activity of 2-Naphthylamine	15450435
D015081	2-Naphthylamine	NAT1 protein results in increased acetylation of 2-Naphthylamine	12618593
D019804	Mesalamine	NAT1 protein results in increased acetylation of Mesalamine	15627487
D010131	Aminosalicylic Acid	NAT1 protein results in increased acetylation of Aminosalicylic Acid	15627487\|1600394
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of NAT1 mRNA	16483693
D000814	Aniline Compounds	NAT1 protein results in increased acetylation of Aniline Compounds analog	15627487
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of NAT1 mRNA	24449571
D001241	Aspirin	Aspirin results in decreased activity of NAT1 protein	15796213
C006680	baicalein	baicalein results in decreased expression of NAT1 mRNA	15796204
C006680	baicalein	baicalein results in decreased expression of NAT1 protein	15796204
C029876	benzidine	NAT1 protein results in increased activity of benzidine	15450435
D001564	Benzo(a)pyrene	NAT1 protein affects the susceptibility to Benzo(a)pyrene	18499698
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of NAT1 mRNA"	19150397
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in increased expression of NAT1 mRNA	20660070
D004958	Estradiol	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of NAT1 mRNA	19619570
D004958	Estradiol	Estradiol results in decreased expression of NAT1 mRNA	23019147
D004958	Estradiol	Estradiol results in increased expression of NAT1 mRNA	19619570
C099952	bifenthrin	bifenthrin results in increased expression of NAT1 mRNA	26071804
C006780	bisphenol A	bisphenol A affects the expression of NAT1 mRNA	25181051
C056005	bromoacetanilide	bromoacetanilide results in decreased activity of NAT1 protein	14714730
C056005	bromoacetanilide	bromoacetanilide results in decreased activity of and results in increased alkylation of NAT1 protein	15106881
D019256	Cadmium Chloride	Cadmium Chloride binds to and results in decreased activity of NAT1 protein	20810355
D019256	Cadmium Chloride	Cadmium Chloride results in decreased methylation of NAT1 promoter	22457795
D002220	Carbamazepine	Carbamazepine results in increased expression of NAT1 mRNA	17112801
D002338	Carotenoids	NAT1 protein polymorphism affects the susceptibility to Carotenoids	15095308
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in increased expression of NAT1 mRNA	17851650
D020245	p-Chloromercuribenzoic Acid	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in increased expression of NAT1 mRNA	26272509
D002995	Clofibric Acid	Clofibric Acid affects the expression of NAT1 mRNA	17602206
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of NAT1 mRNA	24386269
D009249	NADP	[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone	20545351
D003367	Cotinine	NAT1 gene polymorphism affects the abundance of Cotinine	25156213
D003367	Cotinine	NAT1 gene polymorphism affects the reaction [Tobacco Smoke Pollution results in increased abundance of Cotinine]	25156213
D003484	Cyanamide	Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]	22835378
D003484	Cyanamide	Cyanamide results in decreased activity of NAT1 protein	22835378
D016572	Cyclosporine	Cyclosporine results in decreased expression of NAT1 mRNA	20106945\|2383089
D016572	Cyclosporine	Cyclosporine results in decreased expression of NAT1 mRNA	23830897
C089595	cylindrospermopsin	cylindrospermopsin results in increased expression of NAT1 mRNA	23726867
D019314	Dehydroepiandrosterone Sulfate	Dehydroepiandrosterone Sulfate inhibits the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]	11470991
D019314	Dehydroepiandrosterone Sulfate	Dehydroepiandrosterone Sulfate promotes the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]	11470991
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of NAT1 mRNA	21266533
C000944	dicrotophos	dicrotophos results in decreased expression of NAT1 mRNA	28302478
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of NAT1 mRNA	21527772
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of NAT1 mRNA	24535843
C010920	dihydrofolate	dihydrofolate results in decreased activity of NAT1 protein	16003948
D002117	Calcitriol	Calcitriol results in increased expression of NAT1 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of NAT1 mRNA	21592394
D004229	Dithiothreitol	Dithiothreitol inhibits the reaction [Hydrogen Peroxide results in decreased activity of NAT1 protein]	22835378
D004229	Dithiothreitol	Dithiothreitol results in increased activity of NAT1 protein	22835378
D004785	Environmental Pollutants	Environmental Pollutants affects the expression of NAT1 mRNA	19118595
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAT1 mRNA	22079256
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of NAT1 mRNA	23649840
D005419	Flavonoids	Flavonoids results in decreased expression of NAT1 mRNA	18035473
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene analog results in decreased activity of NAT1 protein	15025497
D015073	2-Acetylaminofluorene	NAT1 protein results in decreased acetylation of 2-Acetylaminofluorene	15025497
D015073	2-Acetylaminofluorene	NAT1 protein results in increased activity of 2-Acetylaminofluorene	15450435
D005485	Flutamide	Flutamide results in increased expression of NAT1 mRNA	24793618
D005492	Folic Acid	Folic Acid results in decreased activity of NAT1 protein	16003948
D005492	Folic Acid	Folic Acid results in decreased activity of NAT1 protein modified form	16003948
D005492	Folic Acid	NAT1 protein results in increased acetylation of Folic Acid metabolite	15627487
D005557	Formaldehyde	Formaldehyde results in increased expression of NAT1 mRNA	23649840
D006202	Hair Dyes	NAT1 protein polymorphism affects the susceptibility to Hair Dyes	12663508
D006861	Hydrogen Peroxide	Dithiothreitol inhibits the reaction [Hydrogen Peroxide results in decreased activity of NAT1 protein]	22835378
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased activity of NAT1 protein	15644493\|1924879
D006881	Hydroxyacetylaminofluorene	Hydroxyacetylaminofluorene results in decreased activity of NAT1 protein	15720122
D006881	Hydroxyacetylaminofluorene	Hydroxyacetylaminofluorene results in decreased activity of NAT1 protein	19842618
D007213	Indomethacin	Indomethacin results in increased expression of NAT1 mRNA	16184411
D007460	Iodoacetamide	Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein]	22835378
D007460	Iodoacetamide	Iodoacetamide results in decreased activity of NAT1 protein	22835378
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NAT1 mRNA	25613284
C008261	lead acetate	lead acetate results in increased expression of NAT1 mRNA	22609695
C533894	LG 100815	LG 100815 results in decreased expression of NAT1 mRNA	16951191
C002385	linsidomine	linsidomine results in decreased activity of NAT1 protein	14672957
C042720	mercuric bromide	mercuric bromide results in increased expression of NAT1 mRNA	26272509
D008628	Mercury	Mercury binds to and results in decreased activity of NAT1 protein	20591428
D008727	Methotrexate	Methotrexate results in decreased activity of NAT1 protein	16003948
D008727	Methotrexate	Methotrexate results in decreased activity of NAT1 protein modified form	16003948
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of NAT1 mRNA	23179753\|2718838
D008767	Methylmercury Compounds	Methylmercury Compounds binds to and results in decreased activity of NAT1 protein	20591428
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of NAT1 mRNA	23649840
C001368	N-hydroxy-2-aminofluorene	NAT1 protein results in increased acetylation of N-hydroxy-2-aminofluorene	12088197
C001368	N-hydroxy-2-aminofluorene	NAT1 protein results in increased acetylation of N-hydroxy-2-aminofluorene	12618593
C001365	N-hydroxy-4-acetylaminobiphenyl	N-hydroxy-4-acetylaminobiphenyl results in decreased activity of NAT1 protein	15720122
C001365	N-hydroxy-4-acetylaminobiphenyl	N-hydroxy-4-acetylaminobiphenyl results in decreased activity of NAT1 protein	15720122
C014593	N-hydroxy-4-aminobiphenyl	NAT1 protein results in increased acetylation of N-hydroxy-4-aminobiphenyl	12618593
C014707	nitrosobenzylmethylamine	nitrosobenzylmethylamine results in increased expression of NAT1 mRNA	17616710
C062198	octa-2,4,6-trienoic acid	"octa-2,4,6-trienoic acid results in decreased expression of NAT1 mRNA"	16951191
D017239	Paclitaxel	Paclitaxel results in decreased activity of NAT1 mRNA	17564303
D017239	Paclitaxel	Paclitaxel results in decreased activity of NAT1 protein	17564303
D017239	Paclitaxel	Paclitaxel results in decreased expression of NAT1 mRNA	15015580
C086401	pentabromodiphenyl ether	pentabromodiphenyl ether analog results in decreased expression of NAT1 mRNA	19095052
D010416	Pentachlorophenol	Pentachlorophenol inhibits the reaction [NAT1 protein results in increased acetylation of 4-Aminobenzoic Acid]	11470991
D030421	Peroxynitrous Acid	Peroxynitrous Acid results in decreased activity of NAT1 protein	14672957\|1564449
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of NAT1 mRNA	26272509
D011084	Polycyclic Aromatic Hydrocarbons	NAT1 protein results in increased acetylation of Polycyclic Aromatic Hydrocarbons	15122594
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of NAT1 mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of NAT1 mRNA	22079256
D011342	Procainamide	NAT1 protein results in increased acetylation of Procainamide	16003948
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in increased expression of NAT1 mRNA	20660070
D011763	Pyrrolizidine Alkaloids	Pyrrolizidine Alkaloids results in decreased expression of NAT1 mRNA	26100227
C059514	resveratrol	resveratrol results in increased expression of NAT1 mRNA	19228061
C017947	sodium arsenite	sodium arsenite results in increased expression of NAT1 mRNA	12016162
C017947	sodium arsenite	sodium arsenite results in increased methylation of NAT1 gene	25199682
D012999	Soman	Soman results in increased expression of NAT1 mRNA	19281266
D013418	Sulfamethazine	NAT1 protein results in increased acetylation of Sulfamethazine	16482518
D013467	Sulindac	Sulindac results in decreased expression of NAT1 mRNA	11828994
D013629	Tamoxifen	NAT1 protein results in decreased susceptibility to Tamoxifen	20628863
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of NAT1 mRNA	21592394
D013739	Testosterone	Testosterone results in increased expression of NAT1 mRNA	21592394
D013749	Tetrachlorodibenzodioxin	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of NAT1 mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of NAT1 mRNA	19619570\|2163298
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of NAT1 mRNA	28213091
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NAT1 mRNA	25613284
C009495	titanium dioxide	titanium dioxide results in increased expression of NAT1 mRNA	23409001
D014028	Tobacco Smoke Pollution	NAT1 gene polymorphism affects the reaction [Tobacco Smoke Pollution results in increased abundance of Cotinine]	25156213
D014028	Tobacco Smoke Pollution	NAT1 gene polymorphism affects the susceptibility to Tobacco Smoke Pollution	25156213
D014028	Tobacco Smoke Pollution	NAT1 protein affects the susceptibility to Tobacco Smoke Pollution	18499698
D014051	Toluene 2,4-Diisocyanate	"NAT1 gene polymorphism affects the susceptibility to Toluene 2,4-Diisocyanate"	18447907
D014051	Toluene 2,4-Diisocyanate	"NAT1 protein polymorphism results in increased susceptibility to Toluene 2,4-Diisocyanate"	11927838
D014241	Trichloroethylene	NAT1 gene polymorphism results in increased susceptibility to Trichloroethylene	19834256
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of NAT1 mRNA"	26179874
D014520	Urethane	Urethane results in increased expression of NAT1 mRNA	28818685
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NAT1 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of NAT1 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased methylation of NAT1 gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of NAT1 mRNA	19101580\|2317975
C085514	wogonin	wogonin results in decreased expression of NAT1 mRNA	15816529
C085514	wogonin	wogonin results in decreased expression of NAT1 protein	15816529
C016837	zinc chloride	zinc chloride results in increased expression of NAT1 mRNA	16973896

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004060	arylamine N-acetyltransferase activity	-	IBA	21873635
GO:0004060	arylamine N-acetyltransferase activity	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006805	xenobiotic metabolic process	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005829	cytosol	-	TAS	-

KEGG ID	KEGG Term
hsa00232	Caffeine metabolism
hsa00983	Drug metabolism - other enzymes
hsa01100	Metabolic pathways

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-156580	Phase II - Conjugation of compounds	TAS
R-HSA-156582	Acetylation	TAS
R-HSA-211859	Biological oxidations	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
9288889	Immunochemical, 32P-postlabeling, and GC/MS detection of 4-aminobiphenyl-DNA adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation, and peroxidation. (1997 Aug 1)	Culp SJ	Mutat Res
9806162	A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. (1998 Oct)	Katoh T	Carcinogenesis
12376500	XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. (2002 Oct)	Stern MC	Cancer Epidemiol Biomarkers Prev
11034589	Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. (2000 Nov)	Yu MW	Gut
16003747	NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. (2006 Jan 1)	Carreon T	Int J Cancer
23569127	N-acetyltransferase 1 polymorphism and bladder cancer susceptibility: a meta-analysis of epidemiological studies. (2013 Feb)	Wu K	J Int Med Res
10507782	Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. (1999 Oct)	Hsieh FI	Br J Cancer
12097450	Expression of N-acetyltransferases in periodontal granulation tissue. (2002 May)	Meisel P	J Dent Res
10208649	Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. (1999 Feb)	Henning S	Pharmacogenetics
12037246	Organic solvent exposure, genes, and risk of neuropsychological impairment. (2002 Jun)	Dick F	QJM
12552951	Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. (2002 Nov-Dec)	Wang CY	Anticancer Res
18499698	Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. (2008 Jun)	Suzuki H	Carcinogenesis
12074508	Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: results from a Dutch prospective study. (2002 May)	Tiemersma EW	Cancer Causes Control
14556228	Metabolic polymorphisms and the micronucleus frequency in buccal epithelium of adolescents living in an urban environment. (2003)	Montero R	Environ Mol Mutagen
16112301	NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. (2005 Aug 20-26)	Garcia-Closas M	Lancet
14618622	Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas. (2004 Jan 1)	Tiemersma EW	Int J Cancer
16049806	Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands). (2005 Aug)	van der Hel OL	Cancer Causes Control
15095308	Carotenoids/vitamin C and smoking-related bladder cancer. (2004 Jun 20)	Castelao JE	Int J Cancer
18006927	Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. (2007 Nov)	Jiao L	Cancer Epidemiol Biomarkers Prev
20931357	Lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade, or stage among smokers in Finland. (2011 Feb)	Kidd LR	Biochem Genet
24449363	Association of CYP1A1 and CYP2D6 gene polymorphisms with head and neck cancer in Tunisian patients. (2014)	Khlifi R	Mol Biol Rep
14564055	Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk. (2001)	Jaskula-Sztul R	J Appl Genet
11532862	Real-time PCR analysis of the N-acetyltransferase NAT1 allele 3, 4, 10, 11, 14 and 17 polymorphism in squamous cell cancer of head and neck. (2001 Sep)	Fronhoffs S	Carcinogenesis
20801937	N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population. (2011 Jul)	Djordjevic N	J Clin Pharmacol
9255556	Interaction between dose and susceptibility to environmental cancer: a short review. (1997 Jun)	Hietanen E	Environ Health Perspect
23660777	Association of NAT1 and NAT2 genes with nonsyndromic cleft lip and palate. (2013 Jul)	Song T	Mol Med Rep
8895986	Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. (1996)	Badawi AF	Prog Clin Biol Res
14601045	Genetic polymorphisms and modulation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-DNA adducts in human lymphocytes. (2003 Dec 20)	Magagnotti C	Int J Cancer
11266080	Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. (2001 Mar)	Wikman H	Pharmacogenetics
10585581	Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. (2000 Jan 1)	Katoh T	Int J Cancer
8412184	Metabolic activation, DNA adducts, and H-ras mutations in human neoplastic and non-neoplastic laryngeal tissue. (1993)	Stern SJ	J Cell Biochem Suppl
19368118	MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. (2009 Jan-Feb)	Iguchi T	In Vivo
22645715	Xenobiotic metabolizing gene variants and renal cell cancer: a multicenter study. (2012)	Heck JE	Front Oncol
20937634	Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. (2010 Nov 1)	Cleary SP	Am J Epidemiol
15959877	The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida. (2005 Jul)	Jensen LE	Birth Defects Res A Clin Mol Teratol
11751443	Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. (2001 Dec)	Le Marchand L	Cancer Epidemiol Biomarkers Prev
10817597	Association of the N-acetyltransferase I gene (NATI) with mild and severe substance abuse. (2000 Apr 27)	Comings DE	Neuroreport
29258340	NAT1 genotypic and phenotypic contribution to urinary bladder cancer risk: a systematic review and meta-analysis. (2018 May)	Dhaini HR	Drug Metab Rev
16906563	Risk of limb deficiency defects associated with NAT1, NAT2, GSTT1, GSTM1, and NOS3 genetic variants, maternal smoking, and vitamin supplement intake. (2006 Sep 15)	Carmichael SL	Am J Med Genet A
9107426	Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. (1997 Apr)	Okkels H	Cancer Epidemiol Biomarkers Prev
28714190	Polymorphisms of xenobiotic-metabolizing genes and colorectal cancer risk in patients with lynch syndrome: A retrospective cohort study in Taiwan. (2018 Jan)	Kamiza AB	Environ Mol Mutagen
19664055	Mechanisms and kinetics of human arylamine N-acetyltransferase 1 inhibition by disulfiram. (2009 Sep)	Malka F	FEBS J
10868698	N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. (2000 Jun)	Probst-Hensch NM	Cancer Epidemiol Biomarkers Prev
11431340	Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. (2001 Jul 1)	Cascorbi I	Cancer Res
23899331	Polymorphisms in the N acetyltransferase 1 NAT1 gene and lung cancer risk in a minority population. (1998)	Ishibe N	Biomarkers
16926176	Inherited variation in carcinogen-metabolizing enzymes and risk of colorectal polyps. (2007 Feb)	Goode EL	Carcinogenesis
16847422	Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. (2006 Aug)	Morton LM	Pharmacogenet Genomics
29343473	Smoking affects the interferon beta treatment response in multiple sclerosis. (2018 Feb 13)	Petersen ER	Neurology
15127906	Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms. (2004 Mar)	Lammer EJ	Epidemiology
17675654	Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis. (2007 Oct 1)	Sanderson S	Am J Epidemiol
14612556	p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. (2003 Nov 1)	Schroeder JC	Cancer Res
12869413	No modifying effect of NAT1, GSTM1, and GSTT1 on the relation between smoking and colorectal cancer risk. (2003 Jul)	van der Hel OL	Cancer Epidemiol Biomarkers Prev
9626964	Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers. (1998 Feb 26)	Abdel-Rahman SZ	Mutat Res
11207033	Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. (2001 Feb)	Vaziri SA	Pharmacogenetics
16955540	Bayesian synthesis of epidemiological evidence with different combinations of exposure groups: application to a gene-gene-environment interaction. (2006 Dec 30)	Salanti G	Stat Med
15725609	Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. (2005 Mar 7)	Gu J	Mutat Res
10698485	NAT110 and NAT111 polymorphisms and breast cancer risk. (2000 Feb)	Millikan RC	Cancer Epidemiol Biomarkers Prev
10359544	Colorectal cancer: molecules and populations. (1999 Jun 2)	Potter JD	J Natl Cancer Inst
12835615	NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. (2003 Jul)	van der Hel OL	Pharmacogenetics
25052559	Active cigarette smoking, variants in carcinogen metabolism genes and breast cancer risk among pre- and postmenopausal women in Ontario, Canada. (2014 Sep-Oct)	Cotterchio M	Breast J
11470992	Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1,GSTT1, NAT1 and NAT2. (2001 Jul)	Godschalk RW	Pharmacogenetics
26202054	Interaction between smoking history and gene expression levels impacts survival of breast cancer patients. (2015 Aug)	Andres SA	Breast Cancer Res Treat
17026750	Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women. (2006 Oct 6)	McGrath M	BMC Cancer
27616475	Gene variants as risk factors for gastroschisis. (2016 Nov)	Padula AM	Am J Med Genet A
11107547	[Prevention of renal carcinoma: the nutri-genetic approach]. (2000)	Junien C	J Soc Biol
18449058	Maternal smoking and oral clefts: the role of detoxification pathway genes. (2008 Jul)	Lie RT	Epidemiology
24151610	Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers. (2013)	Khlifi R	Biomed Res Int
21432481	N-Acetyltransferase polymorphism and human cancer risk. (2000 Jan)	Yang X	Environ Health Prev Med
12115538	Genetic susceptibility and gastric cancer risk. (2002 Jul 20)	Gonzalez CA	Int J Cancer
19549810	Meat and heterocyclic amine intake, smoking, NAT1 and NAT2 polymorphisms, and colorectal cancer risk in the multiethnic cohort study. (2009 Jul)	Nothlings U	Cancer Epidemiol Biomarkers Prev
8895478	Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. (1996 Oct)	Probst-Hensch NM	Carcinogenesis
14594555	Relationship of tobacco smoking with GSTM1 gene polymorphism in laringeal cancer. (2003 Jul-Sep)	Bardakci F	J Cell Mol Med
22956951	N-Acetyltransferase 1 (NAT1) Genotype: A Risk Factor for Urinary Bladder Cancer in a Lebanese Population. (2012)	Yassine IA	J Oncol
10090301	N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. (1999 Mar)	Zheng W	Cancer Epidemiol Biomarkers Prev
23803105	Urinary bladder cancer risk factors: a Lebanese case- control study. (2013)	Kobeissi LH	Asian Pac J Cancer Prev
22835378	Cyanamide-mediated Inhibition of N-acetyltransferase 1. (2012 Dec 8)	Dierolf D	Toxicology
15122594	GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. (2004 Jul 1)	Hung RJ	Int J Cancer
12663508	Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. (2003 Mar)	Gago-Dominguez M	Carcinogenesis
22010219	Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent. (2012 Jan)	Millner LM	Drug Metab Dispos
18258609	A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. (2008 Jun)	Zienolddiny S	Carcinogenesis
9610785	Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. (1998 May)	Millikan RC	Cancer Epidemiol Biomarkers Prev
15987714	Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. (2006 Jan)	Li D	Carcinogenesis
21709725	No association between variant N-acetyltransferase genes, cigarette smoking and Prostate Cancer susceptibility among men of African descent. (2011 Feb 3)	Kidd LC	Biomark Cancer
9731715	N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. (1998 Aug)	Bouchardy C	Pharmacogenetics
15746160	Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. (2005 Jul)	Broberg K	Carcinogenesis
21989592	Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. (2012 Mar)	Mikuls TR	Arthritis Rheum
9761125	Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes. (1998 Oct 23)	Bringuier PP	Int J Cancer
24319536	CYP2E1 and NQO1 genotypes and bladder cancer risk in a Lebanese population. (2013)	Basma HA	Int J Mol Epidemiol Genet
19809881	Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. (2010 Jan)	Kilfoy BA	Cancer Causes Control
21097530	Influence of GSTM1, GSTT1, GSTP1, NAT1, NAT2, EPHX1, MTR and MTHFR polymorphism on chromosomal aberration frequencies in human lymphocytes. (2011 Mar)	Skjelbred CF	Carcinogenesis